Home › Carotid Artery Disease › NCT07455747

Real-World Treatment of Extracranial Carotid Artery Disease With the ENROUTE™ Transcarotid Neuroprotection System

Real-World Treatment of Extracranial Carotid Artery Disease With the ENROUTE™ Transcarotid Neuroprotection System (ENTRUST)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patient is ≥ 18 years of age\*
* Written informed consent (patient data-release form)
* Use of ENROUTE™ Transcarotid Neuroprotection System in conjunction with any commercially available Boston Scientific stent marketed for treatment of carotid artery disease and specified in the Registry Enrollment Guide(s).

  * Refer to the Registry Enrollment Guide for details on enrollment restrictions based on patient age

Exclusion Criteria:

* Life expectancy of \< 1 year or patient is unlikely to derive net clinical benefit from carotid revascularization.
* Patient has primary, recurrent or metastatic malignancy and does not have independent assessment of life expectancy of ≥5 years performed by the treating oncologist or an appropriate specialist other than the physician performing TCAR.

About the study

The ENTRUST registry's objective is to collect real-world data (RWD) and health economic data on the ENROUTE™ Transcarotid Neuroprotection System (ENROUTE™ Transcarotid NPS), including populations in which outcomes of Transcarotid Artery Revascularization (TCAR) in patients with extracranial carotid artery disease are inadequately reported.

What is being tested

• Use of ENROUTE™ Transcarotid Neuroprotection System in conjunction with any commercially available Boston Scientific stent marketed for treatment of carotid artery disease (device)

Sponsor: Boston Scientific Corporation · Participants: 5,000 · Started: Aug 19, 2026

Contact the study team

• Erin Hammer · Phone: 952-356-2730

Official record on ClinicalTrials.gov — NCT07455747

Locations in the U.S.

Conditions

• Carotid Artery Disease

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.